Protein kinase inhibitors

Global Checkpoint Kinase Inhibitors Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 29, 2021
Health, Other Health, Drug pipeline, Food and Drug Administration, Pipeline, Protein kinase inhibitors, Pyrimidines

The "Checkpoint Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Checkpoint Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Checkpoint kinase inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Checkpoint kinase inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint kinase inhibitors R&D.
  • Checkpoint kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Aurora-A Kinase Inhibitors Pipeline Insight Report 2021: TransThera Biosciences, Eli Lilly and Co, Takeda Oncology, Wigen Biomedicine, TT-00420, LY-3295668, Alisertib, WJ-05129 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021
Pharmaceutical, Health, Clinical trials, Pipeline, Drug pipeline, Protein kinase inhibitors

The "Aurora-A Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aurora-A Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Aurora-A kinase inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aurora-A kinase inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Aurora-A kinase inhibitors R&D.
  • Aurora-A kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology

Retrieved on: 
Thursday, March 25, 2021
Organic compounds, Chemical compounds, G1 Therapeutics, Chemistry, Protein kinase inhibitors, Lung cancer, Trilaciclib, NCCN, National Comprehensive Cancer Network, Small-cell carcinoma

RESEARCH TRIANGLE PARK, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that COSELA (trilaciclib) has been added to two updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines): the Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that COSELA (trilaciclib) has been added to two updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines): the Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors.
  • We welcome the rapid and simultaneous inclusion in both updated guidelines which reinforces COSELAs clinical utility and importance to patients.
  • The NCCN guidelines are made available free of charge to clinical professionals in the United States and internationally.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, Health, Infectious diseases, Hospitals, Clinical trials, Chemical compounds, Protein kinase inhibitors, Organic compounds, Piperazines, Aminopyridines, Breakthrough therapy, Cyclopentanes, Palbociclib, Breast cancer, Letrozole, HER2/neu, Metastatic breast cancer, the IBRANCE Real-World Evidence Program, IBRANCE® (palbociclib) 125 mg tablets and capsules, Pfizer Oncology, Pfizer: Breakthroughs That Change Patients’ Lives

These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research .

Key Points: 
  • These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research .
  • With more than six years of patient experience, a positive benefit-risk profile, strong clinical data and robust real-world data, the totality of evidence solidifies the role of IBRANCE plus endocrine therapy as a treatment for patients with HR+, HER2- metastatic breast cancer.
  • The analysis also showed the two-year OS rate was 78.3% in the IBRANCE group and 68.0% with letrozole.
  • The findings from this landmark real-world study align with the positive impact that I have seen in my own patients treated with IBRANCE combination therapy.

RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 24, 2021
Enzyme inhibitors, Antineoplastic drugs, Protein kinase inhibitors, Clinical medicine, RET inhibitor, Medicine, Targeted therapy, Drugs, Immune system

NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:
    Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
    RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
    RET Inhibitors In Clinical Trials: > 15 Drugs
    First RET Inhibitor Approved In 2020: Retevmo
    High spaced cancer cases across the globe are leading to the development of several novel and specific targeted therapies like RET inhibitor therapy which has emerged as innovative therapeutic approach.
  • RET inhibitor drug market is highly classified as one of the top and most promising therapeutics sectors in the total cancer therapeutics market.
  • It is believed that in the future years, the entire healthcare applications associated with RET inhibitors, i.e.
  • As per "Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" report findings, it is observed that the market holds the capacity to deliver unrealistic healthcare benefits, inclining the entire therapy to attain a market size and growth rate that is higher than any other cancer therapy.

RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

Retrieved on: 
Wednesday, March 24, 2021
Enzyme inhibitors, Antineoplastic drugs, Protein kinase inhibitors, Clinical medicine, RET inhibitor, Medicine, Targeted therapy, Drugs, Immune system

NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:
    Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
    RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
    RET Inhibitors In Clinical Trials: > 15 Drugs
    First RET Inhibitor Approved In 2020: Retevmo
    High spaced cancer cases across the globe are leading to the development of several novel and specific targeted therapies like RET inhibitor therapy which has emerged as innovative therapeutic approach.
  • RET inhibitor drug market is highly classified as one of the top and most promising therapeutics sectors in the total cancer therapeutics market.
  • It is believed that in the future years, the entire healthcare applications associated with RET inhibitors, i.e.
  • As per "Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026" report findings, it is observed that the market holds the capacity to deliver unrealistic healthcare benefits, inclining the entire therapy to attain a market size and growth rate that is higher than any other cancer therapy.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Retrieved on: 
Tuesday, March 23, 2021
Orphan drugs, Chemical compounds, Organic compounds, Drugs, Chloroarenes, Ureas, Protein kinase inhibitors, Cyclopropanes, Lenvatinib, Merck & Co., Eisai, Thymic carcinoma

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.

Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Tyrosine kinase receptors, Clusters of differentiation, Protein kinase inhibitors, Anaplastic lymphoma kinase, Colony stimulating factor 1 receptor, ALK inhibitor

For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.

Key Points: 
  • For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.
  • For its newest drug candidate, ALK-inhibitor TPX-0131, Turning Point will present preclinical potency data against ALK resistance mutations and in-vivo data demonstrating brain tissue penetration.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics pre-clinical studies and plans regarding future development activities.

Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Branches of biology, Cell Cycle, Biology, Protein kinase inhibitors, Proteins, Breakthrough therapy, Lactams, Palbociclib, Pelareorep, Cyclin-dependent kinase

Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.

Key Points: 
  • Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.
  • New preclinical studies identify the mechanisms of therapeutic synergy between pelareorep and the CDK4/6 inhibitor palbociclib.
  • Data show that combining pelareorep with palbociclib augmented pelareorep-induced endoplasmic reticulum (ER) stress signaling and increased innate immune activation and effector function.
  • Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.

Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Branches of biology, Cell Cycle, Biology, Protein kinase inhibitors, Proteins, Breakthrough therapy, Lactams, Palbociclib, Pelareorep, Cyclin-dependent kinase

Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.

Key Points: 
  • Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding late-breaking abstracts.
  • New preclinical studies identify the mechanisms of therapeutic synergy between pelareorep and the CDK4/6 inhibitor palbociclib.
  • Data show that combining pelareorep with palbociclib augmented pelareorep-induced endoplasmic reticulum (ER) stress signaling and increased innate immune activation and effector function.
  • Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.